FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GLECKEL LOUIS MD
2. Issuer Name and Ticker or Trading Symbol

ProPhase Labs, Inc. [ PRPH ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

621 N. SHADY RETREAT ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

10/1/2019
(Street)

DOYLESTOWN, PA 18901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0005  10/1/2019    A    5740 (1) A $1.96  104330  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  These shares of common stock were issued under the 2010 Directors' Equity Compensation Plan, as amended, pursuant to an election by the Reporting Person to receive shares of common stock of the Issuer in lieu of a cash payment for quarterly director fees.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GLECKEL LOUIS MD
621 N. SHADY RETREAT ROAD
DOYLESTOWN, PA 18901
X



Signatures
/s/ Louis Gleckel, MD 10/3/2019
**Signature of Reporting Person Date


ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more ProPhase Labs Charts.
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more ProPhase Labs Charts.

Prophase Labs, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Thursday 25 April 2024 (7 days ago) • GlobeNewswire Inc.
ProPhase Labs Unveils Project ZenQ-AI
Tuesday 16 April 2024 (2 weeks ago) • GlobeNewswire Inc.
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.
ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
Friday 15 March 2024 (2 months ago) • GlobeNewswire Inc.
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
Friday 8 March 2024 (2 months ago) • GlobeNewswire Inc.
ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART
Tuesday 20 February 2024 (2 months ago) • GlobeNewswire Inc.
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir
Wednesday 14 February 2024 (3 months ago) • GlobeNewswire Inc.
ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics
Tuesday 30 January 2024 (3 months ago) • GlobeNewswire Inc.
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
Tuesday 23 January 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)